Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment

Hiroyuki Fukuda(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Akito Nozaki(Yokohama City University Medical Center), Masaaki Kondo(Yokohama City University Medical Center), Koji Hara(Yokohama City University Medical Center), Masayuki Nakano(Nihon University), Shin Maeda(University of Tokyo Hospital), Akinori Nozawa(Yokohama City University Medical Center), Makoto Chuma(Yokohama City University Medical Center)
Journal of Cancer
January 1, 2018
10.7150/jca.24236
Cited by 8

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333